pubmed:abstractText |
The epidermal growth factor receptor (EGFR) is a mediator of squamous cell carcinoma of the head and neck (SCCHN) development. ZD1839 is an orally active, selective EGFR tyrosine kinase inhibitor. This phase II study sought to explore the activity, toxicity, and pharmacodynamics of ZD1839 in SCCHN.
|
pubmed:affiliation |
Section of Hematology/Oncology, Department of Medicine, University of Chicago, 5841 S Maryland Ave, MC 2115, Chicago, IL 60637-1470, USA. ecohen@medicine.bsd.uchicago.edu
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|